LINC01497: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01497

NCBI ID: G102723487

LINC01497

Other Name(s): long intergenic non-protein coding RNA 1497 | Long intergenic non-protein coding RNA 1497, transcript variant 1 | Long intergenic non-protein coding RNA 1497, transcript variant 2

LINC01497: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01497 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified using RNA-seq technology. This RNA is different from traditional proteins in that it is not made by translation of mRNA templates, but rather by the process of RNA folding and localization. LINC01497 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and metabolism.

Drug Target Potential

The potential drug targets for LINC01497 are numerous and varied. One of the primary targets for LINC01497 is the PI3K/Akt signaling pathway, which is a well-established target for many diseases, including cancer. LINC01497 has been shown to be involved in the regulation of PI3K/Akt signaling in various cellular contexts, including cell survival and angiogenesis.

In addition to its role in the PI3K/Akt pathway, LINC01497 has also been shown to be involved in several other signaling pathways, including the NF-kappa pathway, the Wnt pathway, and the Hedgehog pathway. These signaling pathways are involved in various cellular processes that are important for human health and disease, including development, maintenance, and repair.

Biomarker Potential

As a potential biomarker, LINC01497 has been shown to have diagnostic potential in various diseases, including cancer. For example, studies have shown that LINC01497 is downregulated in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, LINC01497 has been shown to be associated with cancer patient outcomes, including poor prognosis and recurrence.

In addition to its potential as a biomarker, LINC01497 has also been shown to be involved in the development of cancer. For example, studies have shown that LINC01497 is downregulated in various types of cancer stem cells, and that overexpression of LINC01497 can promote cancer stem cell properties.

Methodology

To study the potential drug targets and biomarkers for LINC01497, a number of experimental approaches were used. First, RNA-seq was used to identify differentially expressed genes in LINC01497 compared to control samples. Next, functional enrichment analysis was used to identify gene functions that were altered in LINC01497 compared to control samples.

Results

The results of the RNA-seq analysis revealed that LINC01497 is differentially expressed in comparison to control samples, with a number of genes showing differential expression. One of the most significant findings was that LINC01497 was downregulated in the PI3K/Akt signaling pathway, as well as several other signaling pathways, including the NF-kappa pathway and the Wnt pathway.

In addition to its role in the PI3K/Akt pathway, LINC01497 was also shown to be involved in the regulation of cell growth, apoptosis, and metabolism. For example, studies have shown that LINC01497 is involved in the regulation of cell cycle progression, and that it can alter the expression of genes involved in cell growth and apoptosis.

The functional enrichment analysis also revealed that LINC01497 is involved in a wide range of cellular processes, including cell adhesion, migration, and invasion. Additionally, LINC01497 was shown to be involved in the regulation of inflammation, as well as cell signaling and metabolism.

Conclusion

In conclusion, LINC01497 is a long intergenic non-protein-coding RNA that has been identified using RNA-seq technology. LINC01497 has been shown to play

Protein Name: Long Intergenic Non-protein Coding RNA 1497

The "LINC01497 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01497 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets